Arcutis files Form 144 to sell 3,687 common shares
Arcutis Biotherapeutics reports a proposed sale of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Arcutis Biotherapeutics reports a proposed sale of common stock. The filing lists 3,687 shares of common stock described under "Securities To Be Sold" with an effective date of 03/01/2026. The excerpt also shows a prior sale by Todd Edwards of 2,052 common shares on 02/02/2026.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Arcutis Biotherapeutics' Form 144 show (ARQT)?
Who reported recent sales in the ARQT filing?
Are the securities in the Form 144 restricted or unrestricted (ARQT)?
Does the Form 144 state how proceeds will be used (ARQT)?
What markets or broker information appear in the ARQT excerpt?
AI-generated analysis. How Rhea-AI works. Not financial advice.